Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. (ARCT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
arct · stock forecast · 21 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 21 Wall Street analysts in the past 3 months
Buy
21 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$25.00
Consensus
$22.50
+215.6% upside
Low
$20.00
Median: $22.5 · Last Close: $7.13
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$22.50
215.6% upside
High Target
$25
250.6%
Low Target
$20
180.5%
Current Price
$7.13
as of today
Based on analyst price targets, the ARCT stock price prediction for the next 12 months ranges from $20 to $25. The consensus ARCT price forecast of $22.50 implies 215.6% upside from the current price of $7.13.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $7.12 | ↓ 0.19% |
1-day model range: $7.06–$7.17. Peak: $7.17 (-0.19%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ARCT · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-18 | B. Riley Securities | Upgrade ↑ | Neutral→Buy |
| 2026-03-05 | Citigroup | Maintains | Buy→Buy |
| 2026-03-04 | Piper Sandler | Maintains | Overweight→Overweight |
| 2026-03-04 | Citigroup | Maintains | Neutral→Neutral |
| 2026-01-06 | Citigroup | Maintains | Neutral→Neutral |
| 2025-11-13 | Citigroup | Maintains | Neutral→Neutral |
| 2025-11-11 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2025-11-11 | Piper Sandler | Maintains | Overweight→Overweight |
| 2025-10-24 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-10-23 | Wells Fargo | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Arcturus Therapeutics Holdings Inc. (ARCT) stock. Of the recent 115 rating actions, 9 were upgrades and 21 were downgrades. 21 analysts currently cover ARCT.
Analyst Recommendation Trends
ARCT analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 3 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$16M
↓ 65.5% YoY
Revenue Next Year
$35M
↑ 121.5% YoY
EPS This Year
$-4.06
EPS Next Year
$-3.95
↓ 2.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast ARCT EPS of $-4.06 for the current fiscal year, based on estimates from 8 analysts. The ARCT revenue forecast is $16M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ARCT stock forecast is supported by two independent data sources: analyst consensus ratings from 21 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ARCT price target is $22.50 (+215.6% upside), with an analyst consensus of Buy.
The ARCT short-term stock prediction for tomorrow is $7.12 (-0.19%).
Arcturus Therapeutics Holdings Inc. trades on NASDAQ under the ticker ARCT. The ARCT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 57% of covering analysts.
Frequently asked questions
ARCT forecast · 8 questionsAccording to 21 Wall Street analysts, the average 12-month ARCT price target is $22.50, with a high forecast of $25.00 and a low of $20.00. The median price target is shown in the chart above when available. This implies +215.6% potential upside from the current price of $7.13.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.